SRZN — Surrozen, Inc./DE

—
Nasdaq · Health Care · Biotechnology · CIK 1824893 ·
Last close
$29.98
Market Cap
$571.47M
52W High
$37.83
52W Low
$12.75
ADV30
385,977
Next earnings
—
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 5,000,000 — -10,370,000 50,177,000 115,606,000 102,039,000 334,271,000
Mar 2026 5,000,000 — -10,456,000 -127,505,000 120,709,000 106,910,000 398,856,000
Dec 2025 528,000 — -12,639,000 -183,159,000 98,726,000 89,245,000 286,488,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,550,000
Investing CF
$-225,000
Financing CF
$49,740,000
CapEx
$-225,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-31.44
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-734,337,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-51,107,000
Pretax Income TTM
$-390,211,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$10,528,000
EBITDA
$-50,895,000
Free Cash Flow
$-14,758,875
Enterprise Value
$508,023,136
Total Cash
$100,353,000
Total Debt
$5,837,000
Shares Out
19,061,662
Trailing EPS
$-41.94
Book Value
$-27.90
ROE
—
ROA
-31.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,477,000 -42,092,000 -242,026,000 98,726,000 286,488,000 -187,762,000 -30,244,000
Dec 2024 10,655,000 -25,539,000 -63,564,000 48,467,000 69,847,000 -21,380,000 -17,628,000
Dec 2023 0 -43,028,000 -43,042,000 46,080,000 8,145,000 37,935,000 -40,363,000
Dec 2022 12,500,000 -44,339,000 -36,004,000 89,435,000 13,434,000 76,001,000 -44,145,000

TTM Snapshot

Revenues TTM
$11,511,000
NetIncome TTM
$-332,130,000
OpCashFlow TTM
—
Assets (Latest)
$115,606,000
Forward EPS
$-4.71

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $25.00 · spot: $31.74 · call volume: 87 · put volume: 5

Peers — same industry

TickerNameMarket CapLastDaily %
SANA Sana Biotechnology, Inc. $563.31M $1.88 —
CGEM Cullinan Therapeutics, Inc. $602.14M $9.27 —
FDMT 4D Molecular Therapeutics, Inc. $608.33M $10.79 —
VALN Valneva SE $527.69M $5.57 —
ETRA Electra Therapeutics, Inc. $524.10M $8.35 —

News headlines (Yahoo Finance, 1h cache)

Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock
2026-11-13 13:00 · Yahoo
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 21:05 · Yahoo
Surrozen to Present at Upcoming Healthcare Investor Conference
2026-11-06 21:40 · Yahoo
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
2026-10-20 20:59 · Yahoo
Top Biotech Stock: Guggenheim Names Surrozen as Best Pick
2026-10-15 18:22 · Yahoo
Surrozen secures FDA clearance for SZN-8141 clinical trial
2026-10-05 10:51 · Yahoo
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-10-02 12:00 · Yahoo
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
2026-09-08 12:30 · Yahoo
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
2026-07-22 20:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.